Time from symptom onset to final diagnosis of pulmonary arterial hypertension in Polish patients

Jan Bylica, Marcin Waligóra, Izabella Owsianka, Jerzy Król, Piotr Podolec, Grzegorz Kopeć
2020 Kardiologia polska  
the 1975 Declaration of Helsinki and was approved by the institutional ethics committee. Informed consent was obtained from each study participant. Results and discussion We enrolled 50 patients with PAH (n = 31; 62% women) at the median (IQR) age of 57 ( 45.5-71) years, with idiopathic PAH (n = 40 [80%]) and PAH associated with connective tissue disease (n = 10 [20%]). At the time of enrollment, most patients (n = 45 [90%]) had been previously diagnosed and 5 (10%) patients were newly
more » ... were newly diagnosed. At enrollment, half of the patients presented with the World Health Organization functional class (WHO -FC) III (n = 25 [50%]) followed by WHO -FC II (n = 22 [44%]), IV (n = 2 [4%]), and I (n = 1 [2%]). Our study protocol and main findings are presented in Figure 1. The most common first symptoms of PAH included dyspnea (n = 38 [76%]), tiredness (n = 37 [74%]), and fatigue (n = 35 [70%]). Other initial manifestations reported by patients are listed in Supplementary material, Figure S1 . The median (IQR) number of symptoms reported by each patient was 3 (2-5). More than half of the respondents (n = 26 [52%]) reported that their first symptoms were mild (WHO -FC II). The others reported symptoms typical of WHO -FC I (n = 5 [10%]), III (n = 17 [34%]), and IV (n = 2 [4%]). Most patients reported their first symptoms to general practitioners (GPs; n = 25 [50%]), followed by cardiologists (n = 8 [16%]), or other specialists (n = 4 [8%]) including: 1 pulmonologist, 1 rheumatologist, and 2 physicians without specialization;
doi:10.33963/kp.15344 pmid:32395970 fatcat:cegaryb4cbbcrjqciyfw3ngg3i